Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)

被引：0
|
作者：
Liu, S. V. [1 ]
De Braud, F. [2 ]
Drilon, A. [3 ]
Doebele, R. C. [4 ]
Patel, M. R. [5 ]
Cho, B. C. [6 ]
Ahn, M. J. [7 ]
Chiu, C. H. [8 ]
Farago, A. F. [9 ]
Goto, K. [10 ]
Lee, J. [7 ]
Ohe, Y. [11 ]
Ou, S. H. I. [12 ]
Cassier, P. [13 ]
Tan, D. S. W. [14 ]
Otterson, G. A. [15 ,16 ]
Veronese, L. [17 ]
Osborne, S. [17 ]
Simmons, B. [18 ]
Siena, S. [19 ,20 ]
机构：
[1] Georgetown Univ, Washington, DC 20057 USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Aurora, CO USA
[5] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[6] Yonsei Canc Ctr, Seoul, South Korea
[7] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Tokyo, Japan
[12] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[13] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[14] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[15] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[16] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA
[17] F Hoffmann La Roche Ltd, Basel, Switzerland
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[20] Metropolitano Niguarda, Niguarda Canc Ctr, Grande Osped, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 04期
关键词：
D O I：
10.1016/j.annonc.2021.01.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [41] Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
    Lu, S.
    Fan, Y.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C-C.
    Dong, X.
    Li, J.
    Zhao, J.
    Zhang, Z.
    Zhao, N.
    Xu, T.
    Hou, M.
    Wang, D.
    Hu, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1536 - S1536
  • [42] GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES
    Eichholz, Jordan
    Miao, Emily
    Lebow, Emily
    Walch, Henry
    Flynn, Jessica
    Zhang, Zhigang
    Hubbeling, Harper
    Beal, Kathryn
    Moss, Nelson
    Yu, Kenny
    Yang, Jonathan
    Meng, Alicia
    Kelly, Daniel
    Boerner, Thomas
    Gomez, Daniel
    Rimner, Andreas
    Schultz, Nikolaus
    Drilon, Alexander
    Imber, Brandon
    Pike, Luke
    NEURO-ONCOLOGY, 2022, 24 : 3 - 3
  • [43] Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
    Choudhury, Noura J.
    Woo, Hyung Jun
    Chen, Monica
    Shah, Ronak
    Donoghue, Mark
    Berger, Michael
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2024, 8
  • [44] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Barlesi, F.
    Drilon, A.
    De Braud, F.
    Cho, B. C.
    Ahn, M. J.
    Siena, S.
    Krebs, M. G.
    Lin, C. C.
    John, T.
    Tan, D. S. W.
    Seto, T.
    Dziadziuszko, R.
    Arkenau, H-T.
    Rolfo, C.
    Wolf, J.
    Ye, C.
    Riehl, T.
    Eng, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Drilon, Alexander
    Barlesi, Fabrice
    De Braud, Filippo
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Siena, Salvatore
    Krebs, Matthew G.
    Lin, Chia-Chi
    John, Tom
    Tan, Daniel S. W.
    Seto, Takashi
    Dziadziuszko, Rafal
    Arkenau, Hendrick-Tobias
    Rolfo, Christian
    Wolf, Juergen
    Ye, Chenglin
    Riehl, Todd
    Eng, Susan
    Doebele, Robert C.
    CANCER RESEARCH, 2019, 79 (13)
  • [46] Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer
    Ou, S.
    Cho, B. C.
    Kim, D.
    Drilon, A.
    Lee, J.
    Lin, J.
    Zhu, V.
    Ahn, M.
    Camidge, D. R.
    Stopatschinskaja, S. Shanna
    Liu, J.
    Cui, J.
    Hyman, D.
    Doebele, R.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1047
  • [47] Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
    Doebele, R.
    Perez, L.
    Trinh, H.
    Martinec, M.
    Martina, R.
    Riehl, T.
    Krebs, M.
    Meropol, N.
    Wong, W.
    Crane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S392 - S392
  • [48] Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
    Choudhury, Noura J.
    Woo, Hyung Jun
    Chen, Monica
    Shah, Ronak
    Donoghue, Mark
    Berger, Michael
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2024, 8
  • [49] Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Paz-Ares, L.
    Doebele, R. C.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Blakely, C. M.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Ye, C.
    Simmons, B.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study
    Niho, S.
    Goto, Y.
    Toyozawa, R.
    Daga, H.
    Ohashi, K.
    Takahashi, T.
    Tanaka, H.
    Sakakibara-Konishi, J.
    Hattori, Y.
    Morise, M.
    Kodani, M.
    Ikeda, T.
    Izumi, H.
    Matsumoto, S.
    Yoh, K.
    Nomura, S.
    Goto, K.
    ESMO OPEN, 2024, 9 (08)
12345